Trials / Completed
CompletedNCT05215379
Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
Multicenter Prospective Randomized Clinical Trial of Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 201 (actual)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
At present, there are no relevant studies or reports on the effect of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer. Studied in this paper combin neoadjuvant chemoradiation with immune therapy, carry out "Multicenter prospective randomized clinical trial of neoadjuvant chemoradiation therapy combined with immunotherapy for MSS ultra-low rectal cancer" in order to provide a high-level evidence-based medical evidence for ultra-low rectal cancer treatment and improve ultra-low rectal cancer diagnosis and treatment effect.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | xintilimab injection | neoadjuvant chemoradiation therapy +xintilimab injection 200mg/3week 4cycle |
| OTHER | Control | neoadjuvant chemoradiation therapy |
Timeline
- Start date
- 2022-10-01
- Primary completion
- 2024-12-30
- Completion
- 2025-06-24
- First posted
- 2022-01-31
- Last updated
- 2026-01-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05215379. Inclusion in this directory is not an endorsement.